According to TipRanks, Vane is ranked #6440 out of 7941 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Siemens Healthineers AG with a $59.26 average price target, implying a 26.25% upside from current levels. In a report released today, J.P. Morgan also maintained a Buy rating on the stock with a EUR63.10 price target.
Based on Siemens Healthineers AG’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.19 billion and a net profit of $363 million. In comparison, last year the company earned a revenue of $5 billion and had a net profit of $390 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.